Bridge Biotherapeutics, Inc. (KOSDAQ: 288330)

Market Cap	182.55B
Revenue (ttm)	-340.00
Net Income (ttm)	-33.11B
Shares Out	45.81M
EPS (ttm)	-1,243.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,053,721
Open	3,675.00
Previous Close	3,635.00
Day's Range	3,515.00 - 3,985.00
52-Week Range	1,464.17 - 5,500.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Bridge Biotherapeutics

Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration wit...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 35
• Stock Exchange: KOSDAQ
• Ticker Symbol: 288330

Financial Performance

In 2023, Bridge Biotherapeutics's revenue was 100.00 million, a decrease of -96.69% compared to the previous year's 3.02 billion. Losses were -42.32 billion, 1.49% more than in 2022.